These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24588736)

  • 1. Targeting drug resistance to close the gap in diffuse large B-cell lymphoma.
    Rund D
    Leuk Lymphoma; 2014 Sep; 55(9):1966-7. PubMed ID: 24588736
    [No Abstract]   [Full Text] [Related]  

  • 2. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
    George A; Tam CS; Seymour JF
    Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 4. Double-hit diffuse large B-cell lymphoma.
    Friedberg JW
    J Clin Oncol; 2012 Oct; 30(28):3439-43. PubMed ID: 22949152
    [No Abstract]   [Full Text] [Related]  

  • 5. CD30, another useful predictor of survival in DLBCL?
    Chan WC
    Blood; 2013 Apr; 121(14):2582-3. PubMed ID: 23557969
    [No Abstract]   [Full Text] [Related]  

  • 6. TP53 mutations and rituximab-CHOP.
    Gisselbrecht C
    Blood; 2012 Nov; 120(19):3867-9. PubMed ID: 23144158
    [No Abstract]   [Full Text] [Related]  

  • 7. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
    Fowler NH
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
    Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
    Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
    [No Abstract]   [Full Text] [Related]  

  • 9. TP53 and outcome in DLBCL: not only the coding region.
    Jardin F; Coiffier B
    Blood; 2013 May; 121(22):4433-4. PubMed ID: 23723442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. There is life in the old dog yet: thymidine kinase as predictive marker in diffuse large B-cell lymphoma.
    Wendtner CM
    Leuk Lymphoma; 2013 Nov; 54(11):2343-4. PubMed ID: 23725391
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemo-immunotherapy dosing in older patients with diffuse large B-cell lymphoma: is this how we should treat our parents?
    Link BK
    Leuk Lymphoma; 2012 Aug; 53(8):1435-6. PubMed ID: 22397718
    [No Abstract]   [Full Text] [Related]  

  • 12. Is radiotherapy still necessary for diffuse large B-cell lymphoma therapy?
    Mondello P; Cuzzocrea S; Pitini V; Aloisi C; Mian M
    Acta Oncol; 2015 Jun; 54(6):953-5. PubMed ID: 25831143
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.
    Nobili S; Napoli C; Puccini B; Landini I; Perrone G; Brugia M; Benelli G; Doria M; Martelli M; Finolezzi E; Di Rocco A; Del Fava E; Rigacci L; Di Lollo S; Bosi A; Mini E
    Leuk Lymphoma; 2014 Sep; 55(9):2071-8. PubMed ID: 24289107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
    Pfreundschuh M
    J Clin Oncol; 2012 Oct; 30(28):3433-5. PubMed ID: 22949148
    [No Abstract]   [Full Text] [Related]  

  • 15. [Significance and application of c-myc in diffuse large B-cell lymphoma].
    Huang WT; Lü N; Guo L
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
    Coiffier B; Salles G
    Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
    Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
    Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
    [No Abstract]   [Full Text] [Related]  

  • 18. New high-risk molecular subtypes of DLBCL identified.
    Killock D
    Nat Rev Clin Oncol; 2019 Feb; 16(2):68. PubMed ID: 30560951
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
    Lai S; Venugopal P; Leslie W
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):134-6. PubMed ID: 22402359
    [No Abstract]   [Full Text] [Related]  

  • 20. The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Leuk Lymphoma; 2017 Mar; 58(3):736-739. PubMed ID: 27686739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.